Related Experiment Videos
Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma
Summary
Recombinant alpha-2 interferon (INTRON) showed efficacy in relapsing or refractory myeloma patients, improving bone pain and survival. The treatment was generally well-tolerated, warranting further investigation in new patient groups.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Relapsed or refractory myeloma presents significant treatment challenges, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant alpha-2 interferon (INTRON) in patients with relapsing or refractory multiple myeloma.
- To assess treatment response rates, duration of response, and impact on survival.
Main Methods:
- A multicenter phase II study involving 38 evaluable patients with relapsing or refractory myeloma.
- Patients received INTRON via intravenous and/or subcutaneous administration.
- Prior treatment history and response to therapy were recorded.
Main Results:
- Overall response rates were 10.5% in refractory patients and 26.3% in relapsing patients.
- Three responders maintained response for over a year with maintenance therapy.
- Significant improvement in survival was observed for responders compared to non-responders.
- INTRON was well-tolerated, with manageable hematologic toxicity and no development of neutralizing factors.
Conclusions:
- Recombinant alpha-2 interferon demonstrates activity in relapsing or refractory multiple myeloma.
- INTRON offers a potential treatment option with a favorable safety profile.
- Further trials are recommended to explore INTRON's efficacy in previously untreated myeloma patients.